Show source-provided references
3. Update on the Diagnosis and Treatment of Hepatocellular Carcinoma
5. Targeted Co-Delivery of PD-L1 Monoclonal Antibody and Sorafenib to Circulating Tumor Cells via Platelet-Functionalized Nanocarriers
10.1016/j.bbrc.2023.05.124 ↗8. Espejo-Cruz, M.L., González-Rubio, S., Zamora-Olaya, J., Amado-Torres, V., Alejandre, R., Sánchez-Frías, M., Ciria, R., De La Mata, M., Rodríguez-Perálvarez, M., and Ferrín, G. (2021). Circulating Tumor Cells in Hepatocellular Carcinoma: A Comprehensive Review and Critical Appraisal. Int. J. Mol. Sci., 22.
10.3390/ijms222313073 ↗9. Quantified Postsurgical Small Cell Size CTCs and EpCAM+ Circulating Tumor Stem Cells with Cytogenetic Abnormalities in Hepatocellular Carcinoma Patients Determine Cancer Relapse
10.1016/j.canlet.2017.10.004 ↗12. Fan, Q., Tian, H., Cheng, J., Zou, J., Luan, F., Qiao, J., Zhang, D., Tian, Y., Zhai, B., and Guo, D. (2024). Research Progress of Sorafenib Drug Delivery System in the Treatment of Hepatocellular Carcinoma: An Update. Biomed. Pharmacother., 177.
10.1016/j.biopha.2024.117118 ↗13. Zhang, Y., Zhang, W., Wang, Y., Zhu, J., Zhou, M., Peng, C., He, Z., Sun, J., Li, Z., and Gui, S. (2021). Emerging Nanotaxanes for Cancer Therapy. Biomaterials, 272.
10.1016/j.biomaterials.2021.120790 ↗14. Strategies and Challenges to Improve the Performance of Tumor-Associated Active Targeting
10.1039/D0TB00289E ↗15. Curcumin Analogues and Derivatives with Anti-Proliferative and Anti-Inflammatory Activity: Structural Characteristics and Molecular Targets
10.1080/17460441.2019.1614560 ↗16. Dziubańska-Kusibab, P.J., Nevedomskaya, E., and Haendler, B. (2024). Preclinical Anticipation of On- and Off-Target Resistance Mechanisms to Anti-Cancer Drugs: A Systematic Review. Int. J. Mol. Sci., 25.
10.3390/ijms25020705 ↗17. Therapeutic Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma Recurrence After Liver Transplantation: A Systematic Review and Meta-Analysis
10.5152/tjg.2020.19877 ↗18. Wang, L., Chen, M., Ran, X., Tang, H., and Cao, D. (2023). Sorafenib-Based Drug Delivery Systems: Applications and Perspectives. Polymers, 15.
10.3390/polym15122638 ↗19. Passive and Active Targeting in Cancer Therapy by Liposomes and Lipid Nanoparticles
20. Active Targeting of Drugs and Bioactive Molecules via Oral Administration by Ligand-Conjugated Lipidic Nanocarriers: Recent Advances
10.1208/s12249-018-1262-2 ↗22. Traditional Chinese Medicine-Combination Therapies Utilizing Nanotechnology-Based Targeted Delivery Systems: A New Strategy for Antitumor Treatment
10.2147/IJN.S197889 ↗23. (2024, December 10). Liver Cancer Treatment—NCI, Available online: https://www.cancer.gov/types/liver/what-is-liver-cancer/treatment.
25. Bannangkoon, K., Hongsakul, K., and Tubtawee, T. (2024). Lipiodol Accumulation Patterns and Their Impact on Survival Outcomes in Transarterial Chemoembolization for Hepatocellular Carcinoma: A Single Institution Retrospective Analysis. Sci. Rep., 14.
10.1038/s41598-024-69993-1 ↗26. Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer
10.1016/j.tranon.2020.01.003 ↗28. Prediction of Complete Necrosis of Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Prior to Liver Transplantation
10.5009/gnl.2009.3.4.285 ↗34. Wiergowska, G., Stasiłowicz, A., Miklaszewski, A., Lewandowska, K., and Cielecka-Piontek, J. (2021). Structural Polymorphism of Sorafenib Tosylate as a Key Factor in Its Solubility Differentiation. Pharmaceutics, 13.
10.3390/pharmaceutics13030384 ↗35. Current Status of Sorafenib Nanoparticle Delivery Systems in the Treatment of Hepatocellular Carcinoma
10.7150/thno.54822 ↗36. Modeling and Optimization of Nanoemulsion Containing Sorafenib for Cancer Treatment by Response Surface Methodology
10.1186/s13065-017-0248-6 ↗38. Sorafenib Exhibits Lower Toxicity and Comparable Efficacy to Sunitinib as a First-Line Treatment for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
10.1097/MD.0000000000034983 ↗42. Jiang, H., Wang, C., Zhang, A., Li, Y., Li, J., Li, Z., Yang, X., and Hou, Y. (2022). ATF4 Protects against Sorafenib-Induced Cardiotoxicity by Suppressing Ferroptosis. Biomed. Pharmacother., 153.
10.1016/j.biopha.2022.113280 ↗44. Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors
10.1200/JCO.2005.06.124 ↗45. Sorafenib Improves Lipiodol Deposition in Transarterial Chemoembolization of Chinese Patients with Hepatocellular Carcinoma: A Long-Term, Retrospective Study
10.18632/oncotarget.18811 ↗46. Diagnosis and Management of Hepatocellular Carcinoma: Results of a Consensus Meeting of The Ottawa Hospital Cancer Centre
10.3747/co.v17i2.555 ↗52. Masłowska, K., Halik, P.K., Tymecka, D., Misicka, A., and Gniazdowska, E. (2021). The Role of VEGF Receptors as Molecular Target in Nuclear Medicine for Cancer Diagnosis and Combination Therapy. Cancers, 13.
10.3390/cancers13051072 ↗53. Pottier, C., Fresnais, M., Gilon, M., Jérusalem, G., Longuespée, R., and Sounni, N.E. (2020). Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. Cancers, 12.
10.3390/cancers12030731 ↗54. Preclinical Overview of Sorafenib, a Multikinase Inhibitor That Targets Both Raf and VEGF and PDGF Receptor Tyrosine Kinase Signaling
10.1158/1535-7163.MCT-08-0013 ↗55. Hendrixson, M., Gladkiy, Y., Thyagarajan, A., and Sahu, R.P. (2024). Efficacy of Sorafenib-Based Therapies for Non-Small Cell Lung Cancer. Med. Sci., 12.
10.3390/medsci12020020 ↗56. Leifheit, M.E., Johnson, G., Kuzel, T.M., Schneider, J.R., Barker, E., Yun, H.D., Ustun, C., Goldufsky, J.W., Gupta, K., and Marzo, A.L. (2024). Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia. Int. J. Mol. Sci., 25.
10.3390/ijms25179448 ↗57. Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review
59. Adverse Events of Sorafenib in Hepatocellular Carcinoma Treatment
61. Understanding Sorafenib-Induced Cardiovascular Toxicity: Mechanisms and Treatment Implications
10.2147/DDDT.S443107 ↗62. He, X., Sun, H., Jiang, Q., Chai, Y., Li, X., Wang, Z., Zhu, B., You, S., Li, B., and Hao, J. (2021). Hsa-miR-4277 Decelerates the Metabolism or Clearance of Sorafenib in HCC Cells and Enhances the Sensitivity of HCC Cells to Sorafenib by Targeting cyp3a4. Front. Oncol., 11.
10.3389/fonc.2021.735447 ↗63. Bæk Møller, N., Budolfsen, C., Grimm, D., Krüger, M., Infanger, M., Wehland, M., and Magnusson, N.E. (2019). Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment. Int. J. Mol. Sci., 20.
10.3390/ijms20194712 ↗65. Incidence and Risk of Sorafenib-Induced Hypertension: A Systematic Review and Meta-Analysis
10.1111/jch.12273 ↗66. Hsiao, W.-D., Peng, C.-Y., Chuang, P.-H., Lai, H.-C., Cheng, K.-S., Chou, J.-W., Chen, Y.-Y., Yu, C.-J., Feng, C.-L., and Su, W.-P. (2016). Evaluation of Dose-Efficacy of Sorafenib and Effect of Transarterial Chemoembolization in Hepatocellular Carcinoma Patients: A Retrospective Study. BMC Gastroenterol., 16.
10.1186/s12876-016-0464-x ↗67. Use of Transarterial Chemoembolization (TACE) and Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: US Regional Analysis of the GIDEON Registry
10.1159/000367757 ↗68. TACE Treatment in Patients with Sorafenib-Treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON
10.1148/radiol.2015150667 ↗69. Interim Analysis of START: Study in Asia of the Combination of TACE (Transcatheter Arterial Chemoembolization) with Sorafenib in Patients with Hepatocellular Carcinoma Trial
10.1002/ijc.27925 ↗70. Concurrent Sorafenib Therapy Extends the Interval to Subsequent TACE for Patients with Unresectable Hepatocellular Carcinoma
10.1002/jso.24215 ↗72. Nanoparticle-Based Drug Delivery Systems for Cancer Therapy
73. Mechanisms of Targeted Drug Delivery for Liver Cancer: Active, Passive, and Subcellular Strategies
75. Passive Targeting of Nanoparticles to Cancer: A Comprehensive Review of the Literature
10.3892/mco.2014.356 ↗77. Li, X., Yu, Q., Zhao, R., Guo, X., Liu, C., Zhang, K., Zhang, W., Liu, J., Yu, J., and Wang, S. (2022). Designer Exosomes for Targeted Delivery of a Novel Therapeutic Cargo to Enhance Sorafenib-Mediated Ferroptosis in Hepatocellular Carcinoma. Front. Oncol., 12.
10.3389/fonc.2022.898156 ↗79. N-Acetyl-Galactosamine Modified Metal-Organic Frameworks to Inhibit the Growth and Pulmonary Metastasis of Liver Cancer Stem Cells through Targeted Chemotherapy and Starvation Therapy
10.1016/j.actbio.2022.08.027 ↗80. Apolipoprotein E Peptide-Guided Disulfide-Cross-Linked Micelles for Targeted Delivery of Sorafenib to Hepatocellular Carcinoma
10.1021/acs.biomac.9b01419 ↗82. Shu, M., Tang, J., Chen, L., Zeng, Q., Li, C., Xiao, S., Jiang, Z., and Liu, J. (2021). Tumor Microenvironment Triple-Responsive Nanoparticles Enable Enhanced Tumor Penetration and Synergetic Chemo-Photodynamic Therapy. Biomaterials, 268.
10.1016/j.biomaterials.2020.120574 ↗83. Lin, Z., Li, S., Wu, Q., Qu, H., Shi, X., Wang, K., Tang, C., and Yin, C. (2024). In Situ Customized Apolipoprotein B48-Enriched Protein Corona Enhances Oral Gene Delivery of Chitosan-Based Nanoparticles. Biomaterials, 311.
10.1016/j.biomaterials.2024.122704 ↗84. An Apolipoprotein-Enriched Biomolecular Corona Switches the Cellular Uptake Mechanism and Trafficking Pathway of Lipid Nanoparticles
10.1039/C7NR06437C ↗85. Apolipoprotein E Binding Drives Structural and Compositional Rearrangement of mRNA-Containing Lipid Nanoparticles
10.1021/acsnano.0c10064 ↗87. Diagnostic Imaging and Therapeutic Application of Nanoparticles Targeting the Liver
10.1039/C4TB01611D ↗89. Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment
10.7150/thno.37198 ↗90. EPR-Effect: Utilizing Size-Dependent Nanoparticle Delivery to Solid Tumors
10.4155/tde.13.8 ↗95. Mechanisms of Drug Resistance in HCC
96. Marin, J.J.G., Macias, R.I.R., Monte, M.J., Romero, M.R., Asensio, M., Sanchez-Martin, A., Cives-Losada, C., Temprano, A.G., Espinosa-Escudero, R., and Reviejo, M. (2020). Molecular Bases of Drug Resistance in Hepatocellular Carcinoma. Cancers, 12.
10.3390/cancers12061663 ↗97. (2024, December 24). The Human Protein Atlas. Available online: https://www.proteinatlas.org/.
98. Bismuth-Based Mesoporous Nanoball Carrying Sorafenib for Computed Tomography Imaging and Synergetic Chemoradiotherapy of Hepatocellular Carcinoma
10.1002/adhm.202000650 ↗100. Aconitic Acid Derived Carbon Dots: Conjugated Interaction for the Detection of Folic Acid and Fluorescence Targeted Imaging of Folate Receptor Overexpressed Cancer Cells
10.1016/j.snb.2018.01.227 ↗